Tetrahedron 72 (2016) 4845-4853

Contents lists available at ScienceDirect

Tetrahedron

journal homepage: www.elsevier.com/locate/tet

Facile synthesis of fluorovinyl-containing lactams via ring-closing metathesis of *N*-substituted 2-fluoroallylamides



^a School of Pharmacy, Fudan University, 826 Zhangheng Road, Pudong Zone, Shanghai 201203, China ^b Forxine Pharmaceutical Co., Ltd, 855 Xiangyang Road, Minhang Zone, Shanghai 201203, China

ARTICLE INFO

Article history: Received 25 April 2016 Received in revised form 19 June 2016 Accepted 21 June 2016 Available online 22 June 2016

Keywords: Fluoroolefins Vinyl fluoride Ring-closing metathesis Fluorinated heterocycles Nitrogen heterocycles

ABSTRACT

A cost-efficient method for the preparation of a series of *N*-substituted 2-fluoroallylamines and their application in the synthesis of fluoroalkene-containing lactams are described. *N*-substituted 2-fluoroallylamine could be readily synthesized from methyl 2-fluoroacrylate via aminolysis and subsequently selective reduction of the amide group. These amines were further converted into the corresponding amides with diverse acids bearing a terminal double bond. The Ring-Closing Metathesis (RCM) of the resulting amides led to the formation fluorovinyl-containing lactams in good yields.

separable E/Z isomers.

via RCM reaction.

2. Results and discussion

© 2016 Elsevier Ltd. All rights reserved.

1. Introduction

Fluorinated molecules have a wide range of applications in almost all areas of science.¹ Of particular relevance is the emergence of fluoroolefins, which have appeared as peptidomimetics, bioactive compounds, and materials.² In the medicinal chemistry field, monofluorovinyl group has been described as an isopolar and isosteric mimic of an amide group with increased lipophilicity, membrane permeability and rigidity.³ Recently such fragments have been incorporated in a variety of antiviral, antibacterial, antidiabetic and anticancer agents (Fig. 1),⁴ indicating its importance in drug discovery. It is also extensively utilized as starting material in such synthetic reactions as Diels–Alder reaction, cyclopropanation, polymerization to introduce fluorine atom in the final products.⁵

Nowadays, several methods have been developed for preparing the monofluoroalkenes via direct fluorination of olefin group or fluorine-containing fragment implanting strategies.⁶ Nevertheless, most of those methods have some limitations, such as a narrow range of substrates, poor functional group tolerance, requirement

Retrosynthetic analysis indicates that fluorolactams **6** would be prepared from the 2-fluoroallylamides **5**, which could in turn come

of expensive fluorine-containing reagents, or formation of in-

erful reaction for the preparation of cyclic alkenes owing to its

broad substrate and functional group tolerability, and high regio-

selectivity of the formed double bond.⁶ However, fluoroalkenes

have scarcely been studied in RCM, because there are two inherent

defects to hinder subsequent turnover in the catalytic trans-

formation: slow phosphine dissociation to form the ruthenium

mono-fluorocarbene complex and abnormal stability of the com-

plex.⁷ Recently, a pioneering breakthrough in the challenging RCM

reaction of monofluoroolefins has been achieved by Brown and co-

workers,⁸ and subsequently others have also reported the suc-

cessful RCM reactions with some specific monofluorovinyl de-

monofluorovinyl substrates in RCM remains desirable. Due to their

potential utilities in constrained pseudopeptides and bioactive

heterocycles,¹⁰ herein we describe an efficient preparation of

fluorovinyl-containing lactams from 2-fluoroallylamine derivatives

rivatives.⁹ Therefore, further exploration

The ring-closing metathesis (RCM) is a well-known and pow-





with diverse

The second s

Tetrahedro

^{*} Corresponding author. Tel./fax: +86 21 51980128; e-mail address: leixs@fudan. edu.cn (X. Lei).



Fig. 1. Monofluorovinyl fragments in bioactive compounds.

from the 2-fluoroallylamines **3** through amide formation (Scheme 1). Although **3** could be directly obtained through N-alkylation between the corresponding amines and expensive 2-fluoroallyl chloride, it is more attractive to develop a cost-efficient method for preparation of **3** from the cheap methyl 2-fluoroacrylate through aminolysis reaction and subsequently selective reduction of amides.



Scheme 1. The approach to fluorovinyl-containing lactams.

As shown in Table 1, the aminolysis reaction of methyl 2-fluoroacrylate with 4-methoxybenzyl amine was initially tested under basic conditions. It was noticed that weaker bases such as K_2CO_3 , Et_3N , EtONa, or *t*-BuOK could hardly initiate the aminolysis in the presence of a slight excess amount of the amine. After screening a number of bases, we found that 1.5 equiv of NaHMDS could promote the reaction and give the desired amide **2a** in 64% yield. Thus, a variety of amines were subjected to this condition and could smoothly react with methyl 2-fluoroacrylate, providing the amides **2a**–**i** in moderate to good yields (Table 1).

Compared with 4-methoxybenzyl amine, the benzyl amines with an electron-neutral or withdrawing group on the phenyl ring resulted in slightly lower yields in the aminolysis reaction (**2b**–**2d**, ~55%), however, when aryl amines were used, the yields of aminolysis were greatly improved. All of the aryl amines, regardless of electron-donating or withdrawing substituents on the benzene ring, afforded the desired *N*-aryl 2-fluoroacrylamides in good to excellent yields (**2e**–**2i**, 67–85%).

Subsequently, the selective reduction of the amide group in **2a** was attempted with LiAlH₄. Due to the poor solubility of **2a** in ether

Table 1

The isolated	yields of	N-substituted	2-fluoroacryl	amides (2)	and N-s	ubstituted 2-
fluoroallyl a	mines (3)					

0、_0、	RNH₂ (1.2 eq.)	O _N N,	(i) LiAIH ₄ (5.0 eq.) Et ₂ O/CH ₂ Cl ₂	⊂ ^N .R
F 1	NaHMDS (1.5 eq.) THF rt, overnight	F 2a-i	or (ii) DIBALH (5.0 eq.) THF 0 °C - rt, 3 h	F R: Ar, ArCH ₂ <i>3a-i</i>
Entry	R		Yield	
			2 (%)	3 (%) ^a
1	4-MeO-C ₆ H	I ₄ CH ₂	2a , 64	3a , 52 (32 ^b)
2	C ₆ H ₅ CH ₂		2b , 54	3b , 54
3	4-CF3-C6H4	CH ₂	2c , 56	3c , 53
4	$4-Br-C_6H_4C$	H ₂	2d , 55	3d , 63
5	C_6H_5		2e , 75	3e , 54
6	4-MeO-C ₆ H	l ₄	2f , 70	3f , 56
7	4-CF3-C6H4		2g , 85	3g , 48
8	$3-Br-C_6H_4$		2h , 75	3h , 48
9	2-CH ₃ -C ₆ H	1	2i , 67	3i , 54

 $^{\rm a}\,$ The isolated yield is obtained by reduction with DIBALH unless otherwise noted. $^{\rm b}\,$ Reduction with LiAlH4 (4.0 equiv).

or THF, thus a solution of **2a** in CH_2Cl_2 was added dropwise to the suspension of LiAlH₄ in Et₂O at rt and the selective reduction was rapidly completed. In comparison, decreasing the temperature or the amount of the reducing reagent resulted in a sluggish reaction. In addition, despite the high conversion, the isolated yield was unfortunately low (**3a**, 32%), mainly due to the product adsorption on aluminum salt. On the other hand, the aryl amide (**2e** or **2g**) was subjected to the same condition, the significant amount of the olefin-reduction product was observed. Finally, DIBALH was found as a more suitable reducing reagent for this selective transformation (**3a** 52%, **3e** 54%), and other amides could also be reduced into 2-fluoroallyl amines in acceptable yields (**3b**–**3i**, ~50%), as shown in Table 1.

With a set of 2-fluoroallyl amines in hand, further acylation was performed under the routine condition, aiming at preparing a series of precursors for RCM reaction. The various acids (**4a**–**4e**) tagged with the terminal double bond involving different electronic properties and distances, were converted into acyl chlorides in situ with (COCl)₂ in the presence of a catalytic amount of DMF. Then the acyl chlorides were trapped with the amines (**3a**–**3i**) to give the corresponding amides (**5aa**–**5fe**) in satisfactory yields (61–89%), as described in Table 2.

Table 2

Optimized conditions of RCM reaction with 5ab^a



Entry	Cat. (eq.)	Solv.	Temp (°C)	Yield (%) ^b
1	A (0.30)	CH ₂ Cl ₂	Reflux	8
2	A (0.10)	THF	Reflux	5
3	A (0.10)	Tol	Reflux	38
4	A (0.10)	Tol	80	36
5	A (0.10)	Tol	100	73
6	A (0.20)	Tol	100	67
7	A (0.30)	Tol	100	69
8	A (0.05)	Tol	100	48
9	A (0.10)	Tol	100	16 ^c
10	A (0.10)	Tol	100	60 ^d
11	B (0.10)	Tol	100	46
12	C (0.10)	Tol	100	58

^a Reactions were run for 1 h at the shown temperature after the solution of **5a** (0.5 mmol) in the suitable solvent (0.01 M) had been treated by the catalyst, unless otherwise noted:

^b The isolated yields;

^c The reaction concentration was at 0.10 M;

 $^{\rm d}\,$ The reaction concentration was at 0.005 M.

Next, the RCM reaction was carried out on compound 5ab with catalyst A (Table 2), which was reported to catalyze an efficient RCM reaction.^{8,9} The initial attempt failed to produce the desired **6ab** in refluxing CH₂Cl₂ with 0.1 or 0.3 equiv of catalyst A, although a negligible yield was obtained overnight (Entry 1).⁸ When the reaction was conducted in refluxing THF, similar result was obtained (Entries 2) (see Table 3). However, in refluxing toluene,^{9a,b,e} the RCM reaction yield was increased (Entries 3). Extension of reaction time did not improve the yield, and no reaction was detected at the temperature below 80 °C (Entries 4). These results suggested that the catalyst could promote the RCM reaction at a higher temperature while it might be easily decomposed at that temperature. To keep the catalyst's activity and life span, a solution of the catalyst in toluene was added to the diene solution slowly via a syringe pump over 1 h at 100 °C, and reaction mixture was continued to stir for 1 h. The reaction yield was greatly improved and **6ab** could be obtained in 73% vield (Entries 5).

Subsequently, the catalyst loading and the reaction concentration were further evaluated. No improvement was observed with

Table 3

The acylation of 2-fluoroallyl amines and the subsequent RCM reaction

R ¹ O , OH R ¹ : H, F n: 0-3	1. (COCl) ₂ (1.2 eq.) DMF (cat.) 4a-e (1.3 eq.) CH ₂ Cl ₂ , 0 °C, 1 h 2. 3a-i 0 °C - rt, 1 h		Grubbs II (0.1 eq.) Tol 0 °C, 3 h		$ \begin{array}{c} R^{1} \\ & n^{1} \\ F \\ R^{2} \\ R^{2} \\ R^{1} \\ H \end{array} $
4а-е		5aa-5f e			6aa-6fe
Entry	R	R ¹	n	Yield ^a	
				5 (%)	6 (%)
1	4-MeO-C ₆ H ₄ CH ₂	Н	0	5aa , 61	6aa , 70
2	4-MeO-C ₆ H ₄ CH ₂	Н	1	5ab , 76	6ab , 73
3	4-MeO-C ₆ H ₄ CH ₂	Н	2	5ac , 73	6aa , 48
4	4-MeO-C ₆ H ₄ CH ₂	Н	3	5ad , 79	6ad , 0
5	C ₆ H ₅ CH ₂	Н	1	5bb , 82	6bb , 84
6	4-CF3-C6H4CH2	Н	1	5cb , 89	6cb , 81
7	4-Br-C ₆ H ₄ CH ₂	Н	1	5db , 86	6db , 60
8	C ₆ H ₅	Н	1	5eb , 83	6ef , 83
9	4-MeO-C ₆ H ₄	Н	1	5fb , 82	6fb , 81
10	$4-CF_{3}-C_{6}H_{4}$	Н	1	5gb , 86	6gb , 35
12	2-CH3-C6H4	Н	1	5ib , 78	6ib , 0 ^b
13	4-MeO-C ₆ H ₄	F	0	5fe , 76	6fe, NR ^c

^a The isolated yields;

^b **7ib** could be isolated instead of **6ib**;

^c No reaction.

higher amount of catalyst (0.3 equiv) as compared to a lower one (0.1 equiv), but less amount of catalyst apparently led to a lower yield (Entries 6, 7, 8). On the other hand, reaction concentration also affected the reaction yields. Reaction concentration at 0.01 M appeared to be a better choice than the concentration at 0.005 M (Entries 9, 10). In addition, catalyst B or C, bearing a non-phosphine ligand moiety, often has a superior performance in the case of cross-metathesis with 1-haloethylene or 1,2-dihaloethylene,¹¹ but they did not enhance the catalytic activity for this transformation (Entries 11, 12).

With the optimized condition in hand, our attention was turned to **5aa**, and the five-membered ring product (**6aa**) could smoothly be obtained in 70% yield, similar to the case of the six-membered ring (**6ab**). It has been reported the formation of the five-^{8,9b,d} or seven-^{9b,d,e} membered ring appeared troublesome in the literature. The RCM reaction could still continue to form the seven-membered ring albeit in a lower yield (**6ac**, 48%). However, our reaction condition failed to provide the eight-membered ring (**8ad**, 0%).

As expected, the electronic effect on the benzene ring of *N*-benzyl substituted substrates hardly had an effect on the formation of the six-membered ring, and similar yields were obtained from 60% to 84% (**6ab**, **6bb**, **6cb**, **6db**).

After that, *N*-aryl substituted amides were next examined (**5eb**, **5fb**, **5gb**, **5hb**, **5ib**). To our best knowledge, this type of substrates have never been studied in RCM reaction. The results indicated that the reaction could tolerate diverse functional groups regardless of their *meta* or *para* position on the benzene ring, and smoothly produced the desired *N*-aryl fluorovinyl-containing lactams in moderate to good yields (**6eb**, **6fb**, **6gb**, **6hb**). However, the with-drawing electronic group on benzene ring evidently had a detrimental effect on the metathesis reaction. To our surprise, the substrate (**5ib**) bearing *ortho* methyl on the benzene ring did not undergo the RCM reaction, instead, it was partially transformed into the corresponding α , β -unsaturated amide (**7ib**) through 1,3-*H* shift, suggesting that the *ortho* methyl might hinder the cyclization (shown in eq. 1).



Although metathesis cyclization between one fluoroalkene and the other terminal non-fluorinated alkene went smoothly to provide 5–7 membered lactams, the metathesis between two terminal fluoroalkene partners (**5fe**) failed to provide the desired product (**6fe**) (eq. 2).

Finally, the application of the fluorovinyl-containing lactams was demonstrated in a stereo-selective synthesis of an important building block in the conformation-constrained fluoropseudopeptides, Fmoc-Gly- $\Psi[(E)CF=CH]$ -Gly-OH, *cisoid* mimic of Fmoc-Gly-Gly-OH (eq. 3), which was previously available via poorly stereo-selective method.^{2a,d} Thus, **6ab** was first hydrolyzed in refluxing hydrochloride aqueous solution (6.0 N) for 3 h to afford the corresponding amino acid hydrochloride, and subsequently reacted with Fmoc chloride under basic conditions, giving rise to the *cisoid* mimic **8ab** in 76% yield.

3. Conclusion

In conclusion, a cost-efficient method for preparation of a series of 2-fluoroallylamines from methyl 2-fluoroacrylate has been developed through aminolysis and subsequently selective reduction. Through acylation reaction with diverse acids tagged with terminal olefin moiety, the 2-fluoroallylamines could be transformed into the corresponding precursors for RCM reaction. The RCM reaction with these precursors led to fluorovinyl-containing lactams bearing five-, six- and seven-membered rings, but the reaction between two terminal fluoroalkene partners might be a more challenging task.

4. Experimental section

4.1. General methods and materials

Solvents were distilled from the appropriate drying agents before use. All the reagents were purchased from Acros, Alfa Aesar, and National Chemical Reagent Group Co. Ltd., P. R. China and used as received. The progress of the reactions was monitored by TLC (silica-coated glass plates) and visualized under UV light, and by using iodine or phosphomolybdic acid. Flash column chromatography was performed on silica gel (300–400 mesh). Melting points were measured on a SGW X-4 microscopy melting point apparatus without correction. NMR samples were recorded in CDCl₃ on 400 MHz spectrometers. Chemical shifts (δ) are reported in ppm using TMS (δ =0.0) as an internal standard. Multiplicities of NMR signals are designated as s (singlet), d (doublet), t (triplet), q (quartet), br (broad), m (multiplet, for unresolved lines), etc. ¹³C

NMR and ¹⁹F NMR spectra were recorded on a 150 MHz or 376 MHz spectrometer, respectively. HRMS spectra were recorded on Finnigan-Mat-95 mass spectrometer, equipped with ESI source. Infrared (IR) spectra were recorded neat on KBr tablets with frequencies expressed in cm⁻¹.

4.2. Synthetic procedures and characterization data

4.2.1. General procedure for the synthesis of N-substituted a-fluoroacrylamides (2a-i). A solution of 2.0 M NaHMDS in THF (7.5 mL, 15.0 mmol) was added to the solution of RNH₂ (1.2 equiv) in THF (25 mL) at 0 °C under Ar atmosphere. The reaction solution was then stirred for 30 min at room temperature, after that, methyl 2fluoroacrylate (0.91 mL, 10.0 mmol) was added dropwise at 0 °C. The resulting solution was then warmed to room temperature and stirred for overnight. After quenched with saturated NH₄Cl aqueous solution, the mixture was extracted with EtOAc (2×100 mL), and the combined organic layers were washed with brine (20 mL) and dried over NaSO₄. After filtration and concentration, the residue was purified by column chromatography, and the isolated yields were shown in Table 1.

4.2.1.1. 2-Fluoro-N-(4-methoxybenzyl)-acrylamide (**2a**). Eluent solvent: petroleum ether/ethyl acetate=2/1. White solid, mp 94–95 °C. IR (neat): ν 3258, 2916, 2848, 1640, 1541, 1514, 1371, 1323, 1251, 1177, 988, 827 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 7.25 (d, *J*=7.5 Hz, 2H, ArH), 6.88 (d, *J*=7.5 Hz, 2H, ArH), 6.51 (brs, 1H, NH), 5.72 (dd, *J*=47.8, 1.6 Hz, 1H, CH₂=CF), 5.13 (dd, *J*=15.3, 1.6 Hz, 1H, CH₂=CF), 4.46 (d, *J*=5.6 Hz, 2H, CH₂Ar), 3.80 (d, *J*=0.5 Hz, 3H, OCH₃). ¹³C NMR (150 MHz, CDCl₃): δ 159.3 (d, *J*=28.8 Hz), 159.2, 156.2 (d, *J*=267.8 Hz), 129.3, 114.1, 99.1 (d, *J*=15.5 Hz), 55.2, 42.9. ¹⁹F NMR (376 MHz, CDCl₃): δ -121.6 (ddd, *J*_{H-F(trans)}=47.8 Hz, *J*_{H-F(cis)}=15.3 Hz, *J*=1.9 Hz). HRMS (ESI) *m*/*z*: calcd for C₁₁H₁₃FNO⁺₂ [M+H]⁺ 210.0925, found: 210.0926.

4.2.1.2. 2-Fluoro-N-benzylacrylamide (**2b**). Eluent solvent: petroleum ether/ethyl acetate=5/1. White solid, mp 57–58 °C. IR (neat): ν 3319, 2918, 2849, 1649, 1536, 1497, 1357, 1319, 1208, 1186, 697 cm^{-1. 1}H NMR (400 MHz, CDCl₃) δ 7.44–7.22 (m, 5H, ArH), 6.60 (brs, 1H, NH), 5.74 (dd, *J*=48.0, 3.2 Hz, 1H, CH₂=CF), 5.15 (dd, *J*=15.3, 3.2 Hz, 1H, CH₂=CF), 4.54 (d, *J*=5.8 Hz, 2H, CH₂Ph). ¹³C NMR (150 MHz, CDCl₃) δ 158.8 (d, *J*=31 Hz), 155.6 (d, *J*=270 Hz), 137.3, 128.8, 127.9, 127.8, 99.1 (d, *J*=15 Hz), 43.6. ¹⁹F NMR (376 MHz, CDCl₃) δ – 121.6 (dd, *J*_{H–F(trans)}=48.0 Hz, *J*_{H–F(cis)}=15.2 Hz). HRMS (ESI) *m/z*: calcd for C₁₀H₁₁FNO⁺ [M+H]⁺ 180.0819, found 180.0818.

4.2.1.3. 2-Fluoro-N-(4-(trifluoromethyl)benzyl)acrylamide (**2c**). Eluent solvent: petroleum ether/ethyl acetate=8/1. White solid, mp 100–100 °C. IR (neat): ν 3324, 2917, 2849, 1664, 1540, 1333, 1190, 1166, 920, 899 cm^{-1. 1}H NMR (400 MHz, CDCl₃) δ 7.60 (d, *J*=8.0 Hz, 2H, ArH), 7.40 (d, *J*=8.0 Hz, 2H, ArH), 6.70 (brs, 1H, NH), 5.74 (dd, *J*=47.4, 3.2 Hz, 1H, CH₂=CF), 5.18 (dd, *J*=15.0, 3.2 Hz, 1H, CH₂=CF), 4.59 (d, *J*=6.0 Hz, 2H, CH₂Ar). ¹³C NMR (150 MHz, CDCl₃) δ 159.0 (d, *J*=31.2 Hz), 155.4 (d, *J*=268 Hz), 140.7, 129.6 (q, *J*=32.2 Hz), 127.3, 125.1 (q, *J*=3.3 Hz), 123.6 (q, *J*=270 Hz), 98.9 (d, *J*=14.7 Hz), 42.2. ¹⁹F NMR (376 MHz, CDCl₃) δ -63.10 (s, 3F), -121.8 (dd, *J*_{H=F(trans)}=47.4 Hz, *J*_{H=F(cis)}=15.0 Hz, 1F). HRMS (ESI) *m/z*: calcd for C₁₁H₁₀F₄NO⁺ [M+H]⁺ 248.0693, found 248.0693.

4.2.1.4. 2-Fluoro-N-(4-bromobenzyl) acrylamide (**2d**). Eluent solvent: petroleum ether/ethyl acetate=5/1. White solid, mp 108–109 °C. IR (neat): ν 3329, 2918, 2849, 1650, 1537, 1316, 1207, 1186, 920, 895 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.50–7.30 (m, 2H, ArH), 7.20–7.10 (m, 2H, ArH), 6.65 (brs, 1H, NH), 5.33 (dd, *J*=48.0, 2.2 Hz, 1H, CH₂=CF), 4.76 (dd, *J*=15.6, 2.1 Hz, 1H, CH₂=CF), 4.08 (m, 2H, CH₂Ar). ¹³C NMR (150 MHz, CDCl₃) δ 158.9 (d, *J*=31.0 Hz), 155.4

(d, *J*=268 Hz), 135.7, 131.3, 128.9, 121.1, 98.8 (d, *J*=14.7 Hz), 42.2. ¹⁹F NMR (376 MHz, CDCl₃) δ –121.7 (ddd, *J*_{H-F(*trans*)=47.7 Hz, *J*_{H-F(*cis*)=15.4 Hz, *J*=2.2 Hz). HRMS (ESI) *m/z*: calcd for C₁₀H₁₀BrFNO⁺ [M+H]⁺ 257.9924, found 257.9928.}}

4.2.1.5. 2-*Fluoro-N-phenylacrylamide* (**2e**). Eluent solvent: petroleum ether/ethyl acetate=20/1. White solid, mp 57–58 °C. IR (neat): ν 3349, 2917, 1682, 1661, 1530, 1445, 1329, 1164, 888, 747, 690 cm^{-1.} ¹H NMR (400 MHz, CDCl₃) δ 7.96 (brs, 1H, NH), 7.59 (d, *J*=8.0 Hz, 2H, ArH), 7.37 (m, 2H, ArH), 7.22 (t, *J*=7.6 Hz, 1H, ArH), 5.81 (dd, *J*=47.9, 3.3 Hz, 1H, *CH*₂=CF), 5.26 (dd, *J*=15.4, 3.3 Hz, 1H, *CH*₂=CF). ¹³C NMR (150 MHz, CDCl₃) δ 156.6 (d, *J*=31.0 Hz), 155.8 (d, *J*=268 Hz), 135.9, 128.5, 124.6, 119.6, 99.3 (d, *J*=15.0 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ –121.1 (ddd, *J*_{H–F(trans)}=47.9 Hz, *J*_{H–F(cis)}=15.4 Hz, *J*=5.1 Hz). HRMS (ESI) *m/z*: calcd for C₉H₉FNO⁺ [M+H]⁺ 166.0663, found 166.0662.

4.2.1.6. 2-Fluoro-N-(4-methoxyphenyl)acrylamide (**2f**). Eluent solvent: petroleum ether/ethyl acetate=8/1. White solid, mp 128–109 °C. IR (neat): ν 3438, 3339, 2962, 1680, 1655, 1528, 1414, 1031, 901, 822, 690 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.94 (brs, 1H, NH), 7.49 (d, *J*=9.0 Hz, 2H, ArH), 6.87 (d, *J*=9.0 Hz, 2H, ArH), 5.79 (dd, *J*=47.9, 3.3 Hz, 1H, CH₂=CF), 5.21 (dd, *J*=15.4, 3.3 Hz, 1H, CH₂=CF), 3.79 (s, 3H, OCH₃). ¹³C NMR (150 MHz, CDCl₃) δ 156.5 (d, *J*=34.8 Hz), 154.8 (d, *J*=270 Hz), 128.9, 121.4, 113.6, 98.9 (d, *J*=15.0 Hz), 54.8. ¹⁹F NMR (376 MHz, CDCl₃) δ -121.1 (ddd, *J*_{H-F(trans)}=47.9 Hz, *J*_{H-F(cis)}=15.4 Hz, *J*=4.9 Hz). HRMS (ESI) *m/z*: calcd for C₁₀H₁₁FNO[±]₂ [M+H]⁺ 196.0768, found 196.0770.

4.2.1.7. 2-Fluoro-N-(4-trifluoromethylphenyl)acrylamide (**2g**). Eluent solvent: petroleum ether/ethyl acetate=8/1. Colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 8.10 (brs, 1H, NH), 7.73 (d, *J*=8.4 Hz, 2H, ArH), 6.87 (d, *J*=8.4 Hz, 2H, ArH), 5.85 (dd, *J*=47.6, 3.6 Hz, 1H, CH₂==CF), 5.21 (dd, *J*=15.2, 3.6 Hz, 1H, CH₂==CF). ¹³C NMR (150 MHz, CDCl₃) δ 157.5 (d, *J*=30.0 Hz), 155.8 (d, *J*=270 Hz), 139.6, 127.1 (q, *J*=32.7 Hz), 126.4 (q, *J*=3.4 Hz), 123.9 (q, *J*=270 Hz), 119.9, 100.7 (d, *J*=15.0 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ -121.3 (dd, *J*_{H-F(trans)}=47.9 Hz, *J*_{H-F(cis)}=15.2 Hz, 1F), -62.7 (s, 3F). HRMS (ESI) *m/z*: calcd for C₁₀H₁₁FNO[±] [M+H]⁺ 196.0768, found 196.0770.

4.2.1.8. 2-Fluoro-N-(3-bromophenyl)acrylamide (**2h**). Recrystallization: dichloromethane/ethyl acetate=5/30. White solid, mp 93–94 °C. IR (neat): ν 3438, 3304, 2917, 1682, 1661, 1592, 1536, 1425, 1162, 776, 681 cm^{-1.} ¹H NMR (400 MHz, CDCl₃) δ 7.96 (brs, 1H, NH), 7.86 (d, *J*=2.1 Hz, 1H, ArH), 7.21 (d, *J*=8.1 Hz, 1H, ArH), 6.96 (m, 2H, ArH), 5.79 (dd, *J*=47.8, 3.4 Hz, 1H, CH₂=CF), 5.27 (dd, *J*=16.1, 3.4 Hz, 1H, CH₂=CF). ¹³C NMR (150 MHz, CDCl₃) δ 156.6 (d, *J*=29.7 Hz), 155.1 (d, *J*=270 Hz), 137.1, 129.8, 127.6, 122.5, 122.1, 118.0, 99.8 (d, *J*=14.9 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ –121.4 (ddd, *J*_H–_{F(trans)}=47.8 Hz, *J*_H–_{F(cis})=16.3 Hz, *J*=5.3 Hz). HRMS (ESI) *m/z*: calcd for C₉H₈BrFNO⁺ [M+H]⁺ 243.9768, found 243.9774.

4.2.1.9. 2-Fluoro-N-(o-tolyl)acrylamide (**2i**). Eluent solvent: petroleum ether/ethyl acetate=20/1. White solid, mp 60–61 °C. IR (neat): ν 3443, 3294, 2927, 1687, 1659, 1590, 1530, 1458, 1318, 933, 897, 750 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, *J*=8.0 Hz, 1H, ArH), 7.84 (brs, 1H, NH), 7.30–7.13 (m, 3H, ArH), 5.83 (dd, *J*=48.1, 3.2 Hz, 1H, CH₂=CF), 5.26 (dd, *J*=15.4, 3.2 Hz, 1H, CH₂=CF), 2.29 (s, 3H, ArCH₃). ¹³C NMR (150 MHz, CDCl₃) δ 156.6 (d, *J*=29.3 Hz), 155.7 (d, *J*=270 Hz), 133.8, 129.9, 128.3, 126.3, 125.1, 122.1, 99.2 (d, *J*=15.0 Hz), 16.8. ¹⁹F NMR (376 MHz, CDCl₃) δ –121.2 (dd, *J*H–F(*trans*)=48.2 Hz, *J*H–F(*cis*)=15.6 Hz). HRMS (ESI) *m/z*: calcd for C₁₀H₁₁FNO⁺ [M+H]⁺ 180.0819, found 180.0821.

4.2.2. General procedure for the synthesis of N-substituted 2-fluoroallyl amines (3a-i). A solution of 1.0 M DIBALH in THF

(40 mL, 40 mmol) was added dropwise to the solution of compound 2a-i (8.0 mmol) in dichloromethane (80 mL) within 20 min at 0 °C under Ar atmosphere. The reaction solution was then warmed to room temperature and stirred for overnight. After quenched with saturated NH₄Cl aqueous solution (50 mL), the mixture was filtered, and the filtrate was then extracted with EtOAc (3×100 mL), washed with brine (100 mL) and dried over NaSO₄. After filtration and concentration. The residue was purified by column chromatography, and the isolated yields were shown in Table 1.

4.2.2.1. 2-Fluoro-N-(4-methoxybenzyl)-prop-2-en-1-amine (**3a**). Eluent solvent: dichloromethane/acetone=200/1. Colorless oil. IR (neat): ν 3409, 2955, 2917, 1677, 1662, 1513, 1464, 1247, 1176, 1036, 847 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.25 (d, *J*=8.7 Hz, 2H, ArH), 6.87 (d, *J*=8.7 Hz, 2H, ArH), 4.70 (dd, *J*=17.4, 2.8 Hz, 1H, CH₂=CF), 4.45 (dd, *J*=49.6, 2.8 Hz, 1H, CH₂=CF), 3.80 (s, 3H, OCH₃), 3.75 (s, 2H, CH₂Ar), 3.32 (d, *J*=14.3 Hz, 2H, CH₂NH), 1.60 (brs, 1H, NH). ¹³C NMR (400 MHz, CDCl₃) δ 163.9 (d, *J*=260 Hz), 158.6, 131.6, 129.3, 113.7, 91.4 (d, *J*=10.0 Hz), 55.2, 51.7, 48.4 (d, *J*=30.2 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ -104.4 (ddt, *J*_{H-F(trans)}=49.7 Hz, *J*_{H-F(cis)}=17.4 Hz, *J*=14.3 Hz). HRMS (ESI) *m/z*: calcd for C₁₁H₁₄FNONa⁺ [M+Na]⁺ 218.0952, found 218.0953.

4.2.2.2. 2-Fluoro-N-benzyl-prop-2-en-1-amine (**3b**). Eluent solvent: Petroleum ether/ethyl acetate=2/1. Colorless oil. IR (neat): ν 3338, 3028, 2918, 2846, 1677, 1495, 1454, 1196, 1119, 932, 738, 698 cm^{-1.} ¹H NMR (400 MHz, CDCl₃) δ 7.34 (m, 5H, ArH), 4.70 (dd, *J*=17.1, 2.8 Hz, 1H, CH₂=CF), 4.46 (dd, *J*=49.7, 2.8 Hz, 1H, CH₂=CF), 3.82 (s, 2H, CH₂Ph), 3.34 (d, *J*=14.3 Hz, 2H, CH₂NH). ¹³C NMR (150 MHz, CDCl₃) δ 163.3 (d, *J*=257 Hz), 139.1, 127.8, 127.5, 126.5, 90.8 (d, *J*=18.4 Hz), 51.8, 48.1 (d, *J*=30.3 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ -103.5 (ddt, *J*_{H-F(trans)}=49.7 Hz, *J*_{H-F(cis)}=17.1 Hz, *J*=14.3 Hz). HRMS (ESI) *m*/*z*: calcd for C₁₀H₁₃FN⁺ [M+H]⁺ 166.1027, found 166.1024.

4.2.2.3. 2-Fluoro-N-(4-(trifluoromethyl)benzyl)-prop-2-en-1amine (**3c**). Eluent solvent: dichloromethane. Colorless oil. IR (neat): ν 3423, 2955, 2921, 2849, 1677, 1620, 1326, 1164, 1126, 1019, 850 cm^{-1.} ¹H NMR (400 MHz, CDCl₃) δ 7.59 (d, *J*=8.0 Hz, 2H, ArH), 7.46 (d, *J*=7.9 Hz, 2H, ArH), 4.71 (dd, *J*=17.0, 2.9 Hz, 1H, CH₂=CF), 4.45 (dd, *J*=49.5, 2.9 Hz, 1H, CH₂=CF), 3.87 (s, 2H, CH₂Ar), 3.33 (d, *J*=14.5 Hz, 2H, CH₂NH). ¹³C NMR (150 MHz, CDCl₃) δ 163.6 (d, *J*=257 Hz), 143.2, 128.8 (q, *J*=32.4 Hz), 127.7, 124.7 (q, *J*=4.0 Hz), 123.6 (q, *J*=270 Hz), 91.1 (d, *J*=18.4 Hz), 51.1, 48.1 (d, *J*=30.3 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ -62.8 (s, 3F), -100.0 (ddt, *J*_{H-F(trans)}=49.5 Hz, *J*_{H-F(cis)}=17.0 Hz, *J*=14.5 Hz, 1F). HRMS (ESI) *m/z*: calcd for C₁₁H₁₂F₄N⁺ [M+H]⁺ 234.0900, found 234.0905.

4.2.2.4. 2-Fluoro-N-(4-bromobenzyl)-acrylamide (**3d**). Eluent solvent: petroleum ether/ethyl acetate=10/1. Colorless oil. IR (neat): ν 3338, 2919, 2836, 1677, 1487, 1461, 1197, 1120, 1070, 1011, 932, 855, 799 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.45 (d, *J*=8.0 Hz, 2H, ArH), 7.22 (d, *J*=8.0 Hz, 2H, ArH), 4.69 (d, *J*=17.0 Hz, 1H, CH₂= CF), 4.44 (d, *J*=49.7 Hz, 1H, CH₂=CF), 3.77 (s, 2H, CH₂Ph), 3.31 (d, *J*=14.6 Hz, 2H, CH₂NH). ¹³C NMR (150 MHz, CDCl₃) δ 164.0 (d, *J*=257 Hz), 138.1, 130.9, 129.3, 120.3, 91.0 (d, *J*=18.5 Hz), 51.0, 48.0 (d, *J*=30.0 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ -63.0 (s, 3F), -103.5 (ddt, *J*H-F(trans)=49.6 Hz, *J*H-F(cis)=17.0 Hz, *J*=14.6 Hz, 1F). HRMS (ESI) *m/z*: calcd for C₁₀H₁₂BrFN⁺ [M+H]⁺ 244.0132, found 244.0127.

4.2.2.5. 2-Fluoroallyl-N-aniline (**3e**). Eluent solvent: petroleum ether/ethyl acetate=50/1. Colorless oil. IR (neat): ν 3338, 2919, 2836, 1677, 1487, 1461, 1197, 1120, 1070, 1011, 932, 855, 799 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.25–7.20 (m, 2H, ArH), 6.77 (m, 1H, ArH), 6.69–6.62 (m, 2H, ArH), 4.71 (dd, *J*=17.3, 3.2 Hz, 1H, CH₂=CF), 4.54 (dd, *J*=49.5, 3.2 Hz, 1H, CH₂=CF), 3.90 (brs, NH), 3.88 (d, *J*=8.3 Hz,

2H, *CH*₂NH). ¹³C NMR (150 MHz, CDCl₃) δ 163.5 (d, *J*=258 Hz), 146.4, 128.6, 117.6, 112.5, 90.4 (d, *J*=17.3 Hz), 43.7 (d, *J*=34.9 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ -104.5 (ddt, *J*_{H-F(trans)}=49.5 Hz, *J*_{H-F(cis)}=17.3 Hz, *J*=8.3 Hz). HRMS (ESI) *m/z*: calcd for C₉H₁₁FN⁺ [M+H]⁺ 152.0870, found 152.0869.

4.2.2.6. 2-Fluoroallyl-N-4-methoxyaniline **(3f)**. Eluent solvent: petroleum ether/dichloromethane/ethyl acetate=45/10/1. Colorless oil. IR (neat): *v* 3410, 2934, 2834, 1680, 1514, 1464, 1441, 1236, 1201, 1180, 1036, 932, 855, 820 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 6.89–6.71 (m, 2H, ArH), 6.63 (m, 2H, ArH), 4.70 (dd, *J*=17.3, 2.7 Hz, 1H, *CH*₂=CF), 4.52 (dd, *J*=49.7 Hz, 2.7, 1H, *CH*₂=CF), 3.82 (d, *J*=8.9 Hz, 2H, *CH*₂NH), 3.76 (s, 3H, OCH₃), 3.70–3.50 (brs, 1H, NH). ¹³C NMR (150 MHz, CDCl₃) δ 163.7 (d, *J*=258 Hz), 152.1, 140.6, 114.1 (d, *J*=48.8 Hz), 90.4 (d, *J*=17.7 Hz), 55.1, 44.7 (d, *J*=34.2 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ –104.2 (ddt, *J*_{H-F}(*trans*)=49.7, *J*_{H-F}(*cis*)=17.3, *J*=8.9 Hz). HRMS (ESI) *m/z*: calcd for C₁₀H₁₃FNO⁺ [M+H]⁺ 182.0976, found 182.0972.

4.2.2.7. 2-Fluoroallyl-4-(trifluoromethyl)-N-aniline (**3g**). Eluent solvent: petroleum ether/ethyl acetate=65/1. Colorless oil. IR (neat): ν 3410, 1617, 1528, 1328, 1187, 1162, 1065, 829 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.43 (d, J=8.6 Hz, 2H, ArH), 6.65 (d, J=8.6 Hz, 2H, ArH), 4.70 (dd, J=16.8, 3.2 Hz, 1H, CH₂=CF), 4.52 (dd, J=49.2, 3.2 Hz, 1H, CH₂=CF), 4.29 (brs, 1H, NH), 3.89 (d, J=8.0 Hz, 2H, CH₂NH). ¹³C NMR (150 MHz, CDCl₃) δ 162.3 (d, J=258 Hz), 148.9, 126.7 (q, J=3.4 Hz), 124.1 (q, J=269 Hz), 119.3 (q, J=32.5 Hz), 111.6, 91.6 (d, J=17.2 Hz), 44.7 (d, J=34.2 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ -61.7 (s, 3F), 104.2 (ddt, J_H-F(*trans*)=49.2, J_H-F(*cis*)=16.8, J=8.0 Hz, 1F). HRMS (ESI) *m/z*: calcd for C₁₀H₁₀F₄N⁺ [M+H]⁺ 220.0749, found 220.0735.

4.2.2.8. 2-Fluoroally-3-bromo-N-aniline (**3h**). Eluent solvent: petroleum ether/acetone=50:1. Colorless oil. IR (neat): ν 3426, 2923, 1681, 1596, 1575, 1505, 1482, 1203, 987, 852, 765 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.10–6.90 (m, 1H, ArH), 6.80–6.75 (m, 1H, ArH), 6.70–6.60 (m, 1H, ArH), 6.55 (dd, *J*=8.2, 2.1 Hz, 1H, ArH), 4.72 (dd, *J*=17.2, 3.3 Hz, 1H, CH₂=CF), 4.52 (dd, *J*=49.3, 3.3 Hz, 1H, CH₂=CF), 4.03 (brs, 1H, NH), 3.93–3.72 (m, 2H, CH₂NH). ¹³C NMR (150 MHz, CDCl₃) δ 161.7 (d, *J*=258 Hz), 147.7, 129.9, 122.6, 120.4, 115.1, 111.2, 90.8 (d, *J*=17.1 Hz), 43.48 (d, *J*=35.0 Hz) ¹⁹F NMR (376 MHz, CDCl₃) δ –103.0 to –103.5.0 (m). HRMS (ESI) *m/z*: calcd for C₉H₁₀BrFN⁺ [M+H]⁺ 229.9975, found 229.9979.

4.2.2.9. 2-Fluoroallyl-N-2-methylaniline (**3i**). Eluent solvent: petroleum ether: Acetone=200:1. Colorless oil. IR (neat): ν 3311, 3061, 1657, 1537, 1441, 1314, 1206, 1184, 1045, 920, 893, 748 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.20–7.00 (m, 2H, ArH), 6.80–6.50 (m, 2H, ArH), 4.73 (dd, *J*=17.2, 3.2 Hz, 1H, CH₂=CF), 4.55 (dd, *J*=49.6, 3.2 Hz, 1H, CH₂=CF), 4.02 (brs, 1H, NH), 3.94 (d, *J*=8.3 Hz, 2H, CH₂NH), 2.20 (s, 3H, ArCH₃). ¹³C NMR (150 MHz, CDCl₃) δ 162.6 (d, *J*=257 Hz), 144.4, 129.6, 126.5, 121.7, 117.2, 109.6, 90.4 (d, *J*=17.3 Hz), 43.70 (d, *J*=34.8 Hz), 16.8. ¹⁹F NMR (376 MHz, CDCl₃) δ –104.4 (ddt, *J*_{H-F(trans)}=49.6 Hz, *J*_{H-F(cis)}=17.2 Hz, *J*=8.3 Hz). HRMS (ESI) *m/z*: calcd for C₁₀H₁₃FN⁺ [M+H]⁺ 166.1027, found 166.1028.

4.2.3. General procedure for the acylation of 2-fluoroallyl amines (**5aa–5fe**). Oxalyl dichloride (1.56 mmol, 0.14 mL) was added to the solution of the tested acid (1.72 mmol) in CH₂Cl₂ (5 mL) and DMF (a drop, about 0.05 mL) at 0 °C under Ar atmosphere within 10 min. After the solution was stirred for 3 h at the room temperature, a solution of **3a–i** (1.32 mmol) in dichloromethane (8.0 mL) was added at 0 °C. The reaction solution was then warmed to room temperature and stirred for overnight. After quenched with saturated NaHCO₃ aqueous solution, the mixture was extracted with EtOAc (2×15 mL), and the combined organic layers were washed with brine (20 mL) and dried over NaSO₄. After filtration and

concentration, the residue was purified by column chromatography to give the acylated product with two rotamers, and the isolated yields were shown in Table 2.

4.2.3.1. 2-Fluoroallyl-N-(4-(trifluoromethyl)-N-phenyl-acrylam*ide* (**5aa**). Eluent solvent: petroleum ether/ethyl acetate=1/1. Colorless oil. IR (neat): v 2933, 1651, 1613, 1513, 1441, 1284, 1205, 1176, 1033, 847 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.20 (d, *J*=8.8 Hz, 1H, ArH, one rotamer), 7.08 (d, J=8.4 Hz, 1H, ArH, the other rotamer), 6.87 (d, J=8.8 Hz, 1H, ArH, one rotamer), 6.84 (d, J=8.4 Hz, 2H, ArH, the other rotamer), 6.55-6.51 (m, 1H), 6.48-6.38 (m, 1H), 5.78-5.68 (m, 1H), 4.83-4.67 (m, 1H), 4.61 (m, 1H), 4.59 (m, 1H), 4.52-4.48 (m, 0.5H), 4.40-4.36 (m, 0.5H). 4.13 (d, J=12.8 Hz, 1H), 3.89 (d, J=8.8 Hz, 1H), 3.78 (s, 1.5H), 3.77 (s, 1.5H). ¹³C NMR $(150 \text{ MHz}, \text{CDCl}_3) \delta$ 166.8, 161.2 (d, *J*=258 Hz, one rotamer), 160.7 (d, *I*=258 Hz, one rotamer), 159.2, 159.0, 129.8, 129.5, 129.1, 128.8, 127.9, 127.7, 127.3, 127.2, 114.3, 114.0, 93.0 (d, J=17.3 Hz, one rotamer), 92.4 (d, J=17.2 Hz, one rotamer), 55.3, 50.0, 47.8, 46.3, 45.0 (d, J=32.0 Hz, one rotamer). ¹⁹F NMR (376 MHz, CDCl₃) δ -103.0 to -103.3 (m), δ -104.0 to -104.3 (m). HRMS (ESI) *m/z*: calcd for C₁₄H₁₇FNO⁺₂ [M+H]⁺ 250.1238, found 250.1239.

4.2.3.2. 2-Fluoroallyl-N-(4-methoxybenzyl)-N-but-3-enamide (5ab). Eluent solvent: petroleum ether/ethyl acetate=1/1. Colorless oil. IR (neat): v 2955, 2923, 2850, 1651, 1612, 1513, 1456, 1247, 1174, 1033, 930, 847 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.20 (d, *J*=8.4 Hz, 1H, ArH, one rotamer), 7.09 (d, J=8.4 Hz, 1H, ArH, the other rotamer), 6.87 (d, J=8.4 Hz, 1H, ArH, the other rotamer), 6.84 (d. *I*=8.4 Hz, 1H, ArH, one rotamer), 6.09–5.90 (m, 1H), 5.21–5.16 (m, 1H), 5.21–5.16 (m, 1H), 4.83–4.67 (m, 1H), 4.56 (s, 1H), 4.52 (s, 1H), 4.51–4.33 (m, 1H), 4.08 (d, *J*=14.4 Hz, 1H), 3.84 (d, *J*=8.4 Hz, 1H), 3.80 (s, 1.5H), 3.79 (s, 1.5H), 3.25-3.20 (m, 2H). ¹³C NMR (150 MHz, CDCl₃) δ 171.6, 171.5, 161.4 (d, *J*=261 Hz, one rotamer), 161 (d, *J*=260 Hz, the other rotamer), 159.5, 159.3, 131.6, 131.5, 130.0, 129.2, 128.0, 127.9, 118.3, 118.2, 114.6, 114.2, 93.2 (d, J=18.1 Hz), 92.8 (d, J=18.1 Hz), 55.6, 55.5, 50.3, 47.6, 46.5 (d, J=34.8 Hz), 44.8 (d, I=35.4 Hz), 38.9, 38.6. ¹⁹F NMR (376 MHz, CDCl₃) δ –103.1 to –103.5 (m), -104.0 to -104.3 (m). HRMS (ESI) m/z: calcd for C₁₅H₁₉FNO₂⁺ [M+H]⁺ 264.1394, found 264.1395.

4.2.3.3. 2-Fluoroallyl-N-(4-methoxybenzyl)-N-pent-4-enamide (5ac). Eluent solvent: petroleum ether/ethyl acetate=2/1. Colorless oil. IR (neat): v 3443, 2955, 2923, 2850, 1651, 1612, 1513, 1456, 1247, 1174, 1033, 930, 847 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.16 (d, *J*=8.4 Hz, 1H, ArH, one rotamer), 7.07 (d, *J*=8.4 Hz, 1H, ArH, the other rotamer), 6.88 (d, J=8.4 Hz, 1H, ArH, the other rotamer), 6.84 (d, *J*=8.4 Hz, 1H, ArH, one rotamer), 5.92–5.77 (m, 1H), 5.10–5.03 (m, 1H), 5.01–4.96 (m, 1H), 4.81–4.67 (m, 1H), 4.57 (s, 1H), 4.53 (s, 1H), 4.49-4.33 (m, 1H), 4.08 (d, *J*=13.6 Hz, 1H), 3.84 (d, *J*=8.8 Hz, 1H), 3.80 (s, 1.5H), 3.78 (s, 1.5H), 2.53–2.40 (m, 4H). ¹³C NMR (150 MHz, CDCl₃) δ 172.6, 172.5, 161.4 (d, *J*=260 Hz, one rotamer), 160.8 (d, *I*=260 Hz, the other rotamer), 159.1, 159.0, 137.3, 137.2, 129.7, 129.0, 127.9, 127.6, 115.4, 115.3, 114.3, 114.0, 93.8 (d, J=17.5 Hz), 92.8 (d, J=17.1 Hz), 55.3, 55.2, 49.9, 47.3, 46.2 (d, J=33.4 Hz), 44.7 (d, J=32.0 Hz), 32.5, 32.2, 29.2, 29.1. ¹⁹F NMR (376 MHz, CDCl₃): δ -103.3 to -103.6 (m), -104.1 to -104.4 (m). HRMS (ESI) *m/z*: calcd for C₁₆H₂₁FNO⁺₂ [M+H]⁺ 278.1151, found 278.1156.

4.2.3.4. 2-Fluoroallyl-N-benzyl-N-hex-5-enamide (**5ad**). Eluent solvent: petroleum ether/ethyl acetate=5/1. Colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.17 (d, *J*=8.4 Hz, 1H, ArH, one rotamer), 7.07 (d, *J*=8.4 Hz, 1H, ArH, the other rotamer), 6.88 (d, *J*=8.4 Hz, 1H, ArH, one rotamer), 6.84 (d, *J*=8.4 Hz, 1H, ArH, the other rotamer), 5.92–5.77 (m, 1H), 5.10–4.96 (m, 2H), 4.81–4.67 (m, 1H), 4.57 (s, 1H), 4.53 (s, 1H), 4.49–4.33 (m, 1H), 4.08 (d, *J*=13.6 Hz, 1H), 3.84 (d, *J*=8.8 Hz, 1H), 3.80 (s, 1.5H), 3.78 (s, 1.5H), 2.53–2.40 (m, 2H),

2.30–2.00 (m, 2H), 1.90–1.70 (m, 2H). ¹³C NMR (150 MHz, CDCl₃) δ 173.3, 173.1, 162.0 (d, *J*=260 Hz, one rotamer), 160.8 (d, *J*=260 Hz, the other rotamer), 159.1, 159.0, 138.1, 138.0, 129.7, 129.2, 128.1, 127.7, 115.4, 115.2, 114.3, 114.0, 92.7 (d, *J*=17.5 Hz), 92.3 (d, *J*=17.1 Hz), 55.3, 55.2, 50.0, 47.3, 46.2 (d, *J*=33.4 Hz), 44.7 (d, *J*=32.0 Hz), 33.2, 33.1, 32.4, 32.1, 24.3. ¹⁹F NMR (376 MHz, CDCl₃): δ –103.3 to –103.6 (m), –104.1 to –104.4 (m). HRMS (ESI) *m/z*: calcd for C₁₇H₂₃FNO⁺₂ [M+H]⁺ 292.1707, found 292.1709.

4.2.3.5. 2-Fluoroallyl-N-benzyl-N-but-3-enamide (**5bb**). Eluent solvent: petroleum ether/ethyl acetate=5/1. Colorless oil. IR (neat): ν 3065, 3030, 2982, 2930, 1651, 1495, 1445, 1202, 932, 848, 700 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.51–7.03 (m, 5H, ArH), 6.10–5.50 (m, 1H), 5.50–5.10 (m, 2H), 4.80–4.60 (m, 1H), 4.60–4.50 (m, 2H), 4.50–4.40 (m, 1H), 4.12 (d, *J*=13.8 Hz, 1H), 3.87 (d, *J*=9.1 Hz, 1H), 3.23–3.10 (m, 2H). ¹³C NMR (150 MHz, CDCl₃) δ 170.8, 170.7, 160.7 (d, *J*=259 Hz, one rotamer), 159.3 (d, *J*=259 Hz, the other rotamer), 136.3, 135.5, 130.7, 128.4, 128.1, 127.7, 127.2, 127.0, 125.7, 117.5, 92.3 (d, *J*=17.6 Hz), 92.2 (d, *J*=17.4 Hz), 50.0, 47.4, 45.9 (d, *J*=34.2 Hz), 44.4 (d, *J*=31.7 Hz), 37.9, 37.7. ¹⁹F NMR (376 MHz, CDCl₃) δ –102.0 to –104.0 (m), –104.0 to –106.0 (m). HRMS (ESI) *m/z*: calcd for C₁₄H₁₇FNO⁺ [M+H]⁺ 234.1289, found 234.1291.

4.2.3.6. 2-Fluoroallyl-N-(4-(trifluoromethyl)phenyl-N-but-3enamide (5cb). Eluent solvent: petroleum ether/dichloromethane/ethyl acetate=35/15/1. Colorless oil. IR (neat): ν 2925, 1656, 1413, 1326, 1165, 1125, 1067, 934, 849 cm⁻¹, ¹H NMR (400 MHz, CDCl₃) δ 7.60 (d, *J*=8.0 Hz, 1H, ArH, one rotamer). 7.57 (d. *I*=8.0 Hz, 1H, ArH, the other rotamer), 7.35 (d. *I*=8.0 Hz, 1H, ArH, the other rotamer), 7.29 (d, *J*=8.0 Hz, 1H, ArH, one rotamer), 6.10-5.80 (m, 1H), 5.38-5.00 (m, 2H), 4.82-4.70 (m, 2H), 4.70-4.60 (m, 2H), 4.45-4.25 (m, 1H), 4.12 (d, J=14.4 Hz, 1H), 3.89 (d, *J*=9.2 Hz, 1H), 3.26 (d, 6.5 Hz, 1H), 3.17 (d, 6.5 Hz, 1H). ¹³C NMR (150 MHz, CDCl₃) δ 170.9, 160.6 (d, *J*=259 Hz, one rotamer), 159.8 (d, *I*=259 Hz, the other rotamer), 140.3, 139.7, 130.4, 130.2, 129.0 (q, J=32.3 Hz), 127.8, 125.9, 125.4, 125.0 (q, J=3.1 Hz), 123.4 (q, *I*=270 Hz, one rotamer), 117.7, 117.6, 92.9 (d, *I*=17.7 Hz), 92.5(d, J=17.5 Hz), 49.7, 47.2, 46.5 (d, J=33.6 Hz), 44.6 (d, J=30.9 Hz), 37.9, 37.6. ¹⁹F NMR (376 MHz, CDCl₃) δ –62.9 to –63.0 (m, 3F), –103 to -105 (m, 1F). HRMS (ESI) *m/z*: calcd for C₁₅H₁₅F₄NONa⁺ [M+Na]⁺ 324.0982, found 324.0986.

4.2.3.7. 2-Fluoroallyl-N-(4-bromobenzyl)-N-but-3-enamide (**5db**). Eluent solvent: petroleum ether/dichloromethane/ethyl acetate=30/10/4. Colorless oil. IR (neat): ν 3491, 3080, 3022, 2981, 2932, 1651, 1592, 1488, 1445, 1403, 1220, 1071, 1011, 932, 848, 794 cm^{-1.} ¹H NMR (400 MHz, CDCl₃) δ 7.53–7.39 (m, 2H, ArH), 7.08 (m, 2H, ArH), 6.06–5.90 (m, 1H), 5.23–5.06 (m, 2H), 4.80–4.60 (m, 1H), 4.50–4.40 (m, 2H), 4.40–4.20 (m, 1H), 4.12 (d, *J*=14.0, 1H), 3.85 (d, *J*=9.5 Hz, 1H), 3.24–3.20 (m, 1H), 3.19–3.15 (m, 1H). ¹³C NMR (150 MHz, CDCl₃) δ 170.8, 160.3 (d, *J*=259 Hz), 159.9 (d, *J*=259 Hz), 135.4, 134.5, 131.1, 130.5, 130.4, 129.4, 127.4, 121.1, 120.9, 117.6, 92.7 (d, *J*=17.7 Hz), 92.3 (d, *J*=17.3 Hz), 49.5, 46.9, 46.2 (d, *J*=34.0 Hz), 44.4 (d, *J*=31.5 Hz), 37.8, 37.6. ¹⁹F NMR (376 MHz, CDCl₃) δ –102.0 to –103.0 (m), –103.0 to –106.0 (m). HRMS (ESI) *m/z*: calcd for C₁₄H₁₆BrFNO⁺ [M+H]⁺ 312.0394, found 312.0395.

4.2.3.8. 2-Fluoroallyl-N-phenyl-N-but-3-enamide (**5eb**). Eluent solvent: petroleum ether/ethyl acetate=10/1. White solid, mp 66–67 °C. IR (neat): ν 3497, 3079, 2981, 2933, 1667, 1596, 1495, 1423, 1393, 1195, 933, 848, 702 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.52–7.06 (m, 5H, ArH), 5.89–5.70 (m, 1H), 5.07–4.90 (m, 1H), 4.90–4.70 (m, 1H), 4.65–4.50 (m, 1H), 4.50–4.20 (m, 3H), 2.87–2.70 (m, 2H). ¹³C NMR (150 MHz, CDCl₃) δ 170.4, 160.4 (d, *J*=259 Hz), 141.1, 130.9, 129.0, 127.8, 127.7, 117.3, 93.0 (d, *J*=17.8 Hz), 48.6 (d, *J*=30.7 Hz), 38.7. ¹⁹F NMR (376 MHz, CDCl₃) δ –102.0 to

-104.0 (m). HRMS (ESI) *m/z*: calcd for $C_{13}H_{15}FNO^+$ [M+H]⁺ 220.1132, found 220.1134.

4.2.3.9. 2-Fluoroallyl-N-(4-methoxyphenyl)-N-but-3-enamide (**5fb**). Eluent solvent: petroleum ether/ethyl acetate=10/1. Colorless oil. IR (neat): ν 3078, 2935, 2839, 1665, 1512, 1249, 1195, 1025, 841 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.11 (d, *J*=8.8 Hz, 2H, ArH), 6.90 (d, *J*=8.8 Hz, 2H, ArH), 5.84 (m, 1H, CH=CH₂), 5.05 (dd, *J*=10.2, 1.6 Hz, 1H, CH=CH₂), 4.92 (dd, *J*=17.1, 1.6 Hz, 1H, CH=CH₂), 4.63 (dd, *J*_{H-F(cis)}=16.2 Hz, *J*=3.1 Hz, 1H, CF=CH₂), 4.37 (d, *J*=15.6 Hz, 2H, CH₂NAr), 4.35 (dd, *J*_{H-F(trans)}=48.1 Hz, *J*=3.1 Hz, 1H, CF=CH₂), 3.81 (s, 3H, OCH₃), 2.85 (m, 2H, CH₂CO). ¹³C NMR (150 MHz, CDCl₃) δ 170.7, 161.4 (d, *J*=259 Hz), 158.7, 133.7, 131.0, 128.7, 117.1, 114.1, 93.0 (d, *J*=17.9 Hz), 54.8, 48.7 (d, *J*=30.4 Hz), 38.6. ¹⁹F NMR (376 MHz, CDCl₃) δ -102.0 to -104.0 (m). HRMS (ESI) *m/z*: calcd for C₁₄H₁₆FNO₂Na⁺ [M+Na]⁺ 272.1057, found 272.1064.

4.2.3.10. 2-Fluoroallyl-N-(4-(trifluoromethyl)phenyl-N-but-3enamide (**5gb**). Eluent solvent: petroleum ether/ethyl acetate=10/ 1. Colorless oil. IR (neat): ν 3082, 2932, 1674, 1614, 1423, 1381, 1326, 1169, 1128, 1107, 852 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.71 (d, J=8.2 Hz, 2H, ArH), 7.37 (d, J=8.2 Hz, 2H, ArH), 5.90–5.70 (m, 1H, CH=CH₂), 5.11 (d, J_{H-H(cis)}=10.1 Hz, 1H, CH=CH₂), 4.97 (d, J_{H-H(trans})=17.2 Hz, 1H, CH=CH₂), 4.69 (dd, J_{H-F(cis)}=16.1 Hz, J=3.1 Hz, 1H, CF=CH₂), 4.45 (dd, J_{H-F(trans})=47.6 Hz, J=3.1 Hz, 1H, CF=CH₂), 4.40 (d, J=15.2 Hz, 2H, CH₂NAr), 2.89 (d, J=6.7 Hz, 2H, CH₂CO). ¹³C NMR (150 MHz, CDCl₃) δ 170.0, 160.9 (d, J=276 Hz), 145.0, 131.1, 130.7 (q, J=32.7 Hz), 128.9, 127.0, 123.7 (q, J=270 Hz), 118.4, 94.3 (d, J=17.7 Hz), 49.3 (d, J=30.5 Hz), 39.4. ¹⁹F NMR (376 MHz, CDCl₃) δ –62.9 (s, 3F), –103.2 (ddt, J_{H-F(trans})=47.6 Hz, J_{H-F(cis)}=16.1 Hz, J=15.2 Hz, 1F). HRMS (ESI) m/z: calcd for C₁₃H₁₄F₄NO [M+H]⁺ 288.1006, found 288.1006.

4.2.3.11. 2-Fluoroallyl-N-(3-bromophenyl)-N-but-3-enamide (**5hb**). Eluent solvent: petroleum ether/ethyl acetate=10/1. Colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.53 (d, J=8.0 Hz, 1H, ArH), 7.40 (s, 1H, ArH), 7.32 (m, 1H, ArH), 7.18 (d, J=8.4 Hz, 1H, ArH), 6.00–5.80 (m, 1H, CH=CH₂), 5.11 (d, J=10.1 Hz, 1H, CH=CH₂), 4.97 (d, J=17.2 Hz, 1H, CH=CH₂), 4.69 (dd, J_{H-F(cis)}=16.1, 3.1 Hz, 1H, CF=CH₂), 4.41 (dd, J_{H-F(trans})=47.6 Hz, J=3.1 Hz, 1H, CF=CH₂), 4.40 (d, J=15.6 Hz, 2H, CH₂NAr), 2.89 (d, J=6.7 Hz, 2H, CH₂CO). ¹³C NMR (150 MHz, CDCl₃) δ 170.0, 160.9 (d, J=259 Hz), 142.3, 131.1, 130.9, 130.5, 130.3, 126.5, 122.3, 117.6, 93.4 (d, J=17.7 Hz), 48.6 (d, J=30.5 Hz), 38.7. ¹⁹F NMR (376 MHz, CDCl₃) δ – 102.0 to – 103.0 (m). HRMS (ESI) *m/z*: calcd for C₁₃H₁₄BrFNONa⁺ [M+Na]⁺ 320.0057, found 320.0059.

4.2.3.12. 2-Fluoroallyl-N-(o-tolyl)-N-but-3-enamide (**5ib**). Eluent solvent: petroleum ether/ethyl acetate=10/1. White solid, mp 60–61 °C. IR (neat): ν 3424, 2919, 2849, 1666, 1492, 1393, 1378, 1187, 935, 848, 730 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.40–7.01 (m, 4H, ArH), 5.89 (m, 1H, CH=CH₂), 5.06–5.0 (m, 1H, CH=CH₂), 4.97–4.73 (m, 2H, CH=CH₂, CH₂NAr), 4.65 (dd, J_{H-F(cis)}=16.0 Hz, J=3.0 Hz, 1H, CFCH₂), 4.38 (dd, J_{H-F(trans)}=47.9 Hz, J=3.0 Hz, 1H, CFCH₂), 3.82 (dd, J=18.6, 15.0 Hz, 1H, CH₂NAr), 2.94–2.60 (m, 2H, CH₂CO), 2.22 (s, 3H, CH₃). ¹³C NMR (150 MHz, CDCl₃) δ 170.6, 161.4 (d, J=259 Hz), 139.6, 135.2, 130.8, 130.7, 128.7, 128.2, 126.6, 117.3, 93.5 (d, J=17.9 Hz), 47.6 (d, J=30.1 Hz), 38.4, 16.8. ¹⁹F NMR (376 MHz, CDCl₃) δ –101.5 to –102.0 (m). HRMS (ESI) *m/z*: calcd for C₁₄H₁₇FNO⁺ [M+H]⁺ 234.1289, found 234.1289.

4.2.3.13. 2-Fluoro-N-(2-fluoroallyl)-N-(4-methoxyphenyl)-acrylamide (**5fe**). Eluent solvent: petroleum ether/dichloromethane/ ethyl acetate=15/4/1. Colorless oil. IR (neat): ν 3415, 2916, 2848, 1667, 1644, 1512, 1400, 1249, 1172, 934, 838, 769 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.13–7.11 (m, 2H, ArH), 6.89–6.86 (m, 2H, ArH), 5.26 (dd, $J_{H-F(trans)}$ =45.6 Hz, J=3.2 Hz, 1H, COCFCH₂), 4.98 (dd, $J_{H-F(cis)}$ =12.8 Hz, J=3.2 Hz, 1H, COCFCH₂), 4.70 (dd, $J_{H-F(cis)}$ =16.0 Hz, J=3.2 Hz, 1H, CFCH₂), 4.43 (dd, $J_{H-F(trans)}$ =48.0 Hz, J=3.2 Hz, 1H, CFCH₂), 4.42 (d, J=14.8 Hz, 1H, CH₂N), 3.80 (d, J=1.6 Hz, 3H, OCH₃). ¹³C NMR (150 MHz, CDCl₃) δ 161.1 (d, J=28.9 Hz), 159.8 (d, J=259 Hz), 158.5, 156.3 (d, J=271 Hz), 133.4, 127.4, 113.8, 100.5 (d, J=15.3 Hz), 93.5 (d, J=17.6 Hz), 54.8, 49.9 (d, J=30.8 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ –102.8 to –103.0 (m), –105.9 to –106.1 (m). HRMS (ESI) m/z: calcd for C₁₃H₁₄F₂NO₂⁺ [M+H]⁺ 254.0987, found 254.0992.

4.2.4. General procedure for the synthesis of compound (**Gaa–6fe**). A solution of Grubbs' II (0.145 g, 0.17 mmol) in Tol (40 mL) was added via a syringe pump over 1 h to a solution of compound **5ab–ib** (1.70 mmol) in Tol (150 mL) at 100 °C under Ar atmosphere. After that, the solution continued to stir for another 30 min at the same temperature. The solvent was removed under reduced pressure and the residue was purified by silica gel chromatography, and the isolated yields were shown in Table 2.

4.2.4.1. 4-Fluoro-1-(4-methoxybenzyl)-1H-pyrrol-2(5H)-one (**6aa**). Eluent solvent: petroleum ether/ethyl acetate=2/1. White solid, mp 69–70 °C IR (neat): ν 3447, 2929, 2837, 1652, 1613, 1513, 1441, 1248, 1205, 1038, 933, 847, 819, 794 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.27 (d, *J*=8.6 Hz, 2H, ArH), 6.97 (d, *J*=8.6 Hz, 2H, ArH), 5.62 (s, 1H, *CH*=CF), 4.63 (s, 2H, *CH*₂Ar), 3.93 (s, 2H, *CH*₂N), 3.89 (s, 3H, OCH₃). ¹³C NMR (100 MHz, CDCl₃) δ 173.5 (d, *J*=291 Hz), 169.4 (d, *J*=15 Hz), 159.1, 129.4, 128.6, 114.2, 102.3, 55.3, 48.2 (d, *J*=25.5 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ –108.6 (s). HRMS (ESI) *m/z*: calcd for C₁₂H₁₂FNO₂Na⁺ [M+Na] 244.0744, found 244.0744.

4.2.4.2. 5-Fluoro-1-(4-methoxybenzyl)-1,6-dihydropyridin-2(3H)-one (**6ab**). Eluent solvent: petroleum ether/ethyl acetate=2/ 1. White solid, mp 73–74 °C IR (neat): ν 3442, 2955, 2923, 2850, 1651, 1513, 1456, 1247, 1198, 1174, 1038, 930, 847 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.21 (d, *J*=8.4 Hz, 2H, ArH), 6.86 (d, *J*=8.4 Hz, 2H, ArH), 5.25 (d, *J*=14.0 Hz, 1H, CH=CF), 4.57 (s, 2H, CH₂Ar), 3.83–3.81 (m, 2H, CH₂N), 3.79 (s, 3H, OCH₃), 3.11–3.00 (m, 2H, CH₂CO). ¹³C NMR (100 MHz, CDCl₃): δ 166.1, 159.2, 151.5 (d, *J*=250 Hz), 129.7, 127.8, 114.1, 97.7 (d, *J*=15.0 Hz), 55.2, 49.2, 45.7 (d, *J*=40.0 Hz), 29.9 (d, *J*=12.3 Hz). ¹⁹F NMR (376 MHz, CDCl₃): δ –117.7 to –116.0 (m). HRMS (ESI) *m/z*: calcd for C₁₃H₁₅FNO⁺₂ [M+H] 236.1081, found 236.1080.

4.2.4.3. 6-Fluoro-1-(4-methoxybenzyl)-3,4-dihydro-1H-azepin-2(7H)-one (**6ac**). Eluent solvent: petroleum ether/ethyl acetate=3/ 2. Colorless oil. IR (neat): ν 2920, 2849, 1652, 1611, 1513, 1473, 1246, 1110, 1032, 839, 815 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.18 (d, *J*=12 Hz, 2H, ArH), 6.85 (d, *J*=8.4 Hz, 2H, ArH), 5.43 (dt, *J*=20.4 Hz, *J*=4.0 Hz, 1H, CH=CF), 4.59 (s, 2H, CH₂Ar), 3.92 (d, *J*=12 Hz, 2H, CH₂N), 3.79 (s, 3H, OCH₃), 2.75–2.72 (t, *J*=6.0 Hz, 2H, CH₂CO), 2.43–2.40 (m, 2H, CH₂CH₂CO). ¹³C NMR (100 MHz, CDCl₃): δ 173.7, 159.0, 156.6 (d, *J*=252 Hz), 129.2, 128.7, 114.0, 106.0 (d, *J*=20 Hz), 55.2, 50.6, 46.4 (d, *J*=42 Hz), 33.7, 21.4. ¹⁹F NMR (376 MHz, CDCl₃): δ –98.9 to –99.0 (m). HRMS (ESI) *m/z*: calcd for C₁₄H₁₇FNO[±]₂ [M+H] 250.1238, found 250.1239.

4.2.4.4. 5-Fluoro-1-benzyl-1,6-dihydropyridin-2(3H)-one (**6bb**). Eluent solvent: petroleum ether/dichloromethane/ethyl acetate=10/5/2. White solid, mp 62–63 °C. IR (neat): ν 3462, 2920, 1650, 1489, 1453, 1252, 1181, 1064, 819, 710 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.41–7.22 (m, 5H, ArH), 5.29–5.24 (m, 1H, CH= CF), 4.63 (s, 2H, ArCH₂), 3.85–3.82 (m, 2H, CH₂N), 3.13–3.08 (m, 2H,

CH₂CO). ¹³C NMR (150 MHz, CDCl₃) δ 165.6, 150.6 (d, *J*=250 Hz), 135.3, 128.2, 127.6, 127.2, 97.4 (d, *J*=14.8 Hz), 49.3, 45.3 (d, *J*=39.1 Hz), 29.2 (d, *J*=8.3 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ –116.0 to –116.9 (m). HRMS (ESI) *m/z*: calcd for C₁₂H₁₃FNO⁺ [M+H]⁺ 206.0976, found 206.0974.

4.2.4.5. 5-*Fluoro*-1-(4-(*trifluoromethyl*)*benzyl*)-1,6*dihydropyridin*-2(3*H*)-*one* (**6cb**). Eluent solvent: petroleum ether/ ethyl acetate=5/3. White solid, mp 70–71 °C. IR (neat): *v* 3453, 2924, 1651, 1620, 1489, 1419, 1325, 1169, 1124, 1066, 819 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.61 (d, *J*=8.0 Hz, 2H, ArH), 7.40 (d, *J*=8.0 Hz, 2H, ArH), 5.31 (d, *J*=16.0 Hz, 1H, CH=CF), 4.69 (s, 2H, CH₂Ar), 3.89–3.86 (m, 2H, CH₂N), 3.16–3.12 (m, 2H, CH₂CO). ¹³C NMR (150 MHz, CDCl₃) δ 165.8, 150.3 (d, *J*=250 Hz), 139.4, 129.6 (q, *J*=32.3 Hz), 127.7, 125.2–125.1 (q, *J*=3.8 Hz), 123.4 (q, *J*=270 Hz), 97.6 (d, *J*=15 Hz), 48.9, 45.7 (d, *J*=39.5 Hz), 29.1 (d, *J*=8.4 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ –63.1 (s, 3F), –116.0 to –116.6 (m, 1F). HRMS (ESI) *m/z*: calcd for C₁₂H₁₀F₄NO⁺ [M+H]⁺ 260.0693, found 260.0695.

4.2.4.6. 5-Fluoro-1-(4-bromobenzyl)-1,6-dihydropyridin-2(3H)one (**6db**). Eluent solvent: petroleum ether/ethyl acetate=5/2. White solid, mp 78–79 °C. IR (neat): ν 3455, 2920, 1649, 1488, 1181, 1070, 1012, 817 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.45 (d, *J*=7.6 Hz, 2H, ArH), 7.15 (d, *J*=8.0 Hz, 2H, ArH), 5.27 (d, *J*=12.4 Hz, 1H, CH=CF), 4.57 (s, 2H, CH₂Ar), 3.84–3.82 (m, 2H, CH₂N), 3.12–3.07 (m, 2H, CH₂CO). ¹³C NMR (150 MHz, CDCl₃) δ 165.6, 150.4 (d, *J*=250 Hz), 134.4, 131.3, 129.4, 121.2, 97.5 (d, *J*=14.9 Hz), 48.8, 45.4 (d, *J*=39.5 Hz), 29.2 (d, *J*=8.3 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ –116.0 to –116.9 (m). HRMS (ESI) *m/z*: calcd for C₁₂H₁₂BrFNO⁺₂ [M+H]⁺ 284.0081, found 284.0083.

4.2.4.7. 5-*Fluoro-1-phenyl-1*,6-*dihydropyridin-2(3H)-one* (**6eb**). Eluent solvent: dichloromethane/ethyl acetate=30/1. White solid, mp 102–103 °C. IR (neat): *v* 3421, 2917, 2849, 1645, 1595, 1441, 1368, 1277, 1174, 1140, 749 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.46–7.42 (m, 2H, ArH), 7.35–7.26 (m, 3H, ArH), 5.40 (dt, *J*=14, 1.2 Hz, 1H, CH=CF), 4.33–4.31 (m, 2H, CH₂N), 3.25–3.20 (m, 2H, CH₂CO). ¹³C NMR (150 MHz, CDCl₃) δ 165.8, 150.8 (d, *J*=250 Hz), 140.8, 128.9, 127.0, 125.7, 97.6 (d, *J*=14.7 Hz), 49.4 (d, *J*=39.0 Hz), 29.7(d, *J*=8.7 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ –117.0 to –118.1 (m). HRMS (ESI) *m/z*: calcd for C₁₁H₁₁FNO⁺ [M+H]⁺ 192.0819, found 192.0821.

4.2.4.8. 5-Fluoro-1-(4-methoxyphenyl)-1,6-dihydropyridin-2(3H)-one (**6fb**). Eluent solvent: petroleum ether/ethyl acetate=1/2. White solid, mp 138–139 °C. IR (neat): v 3442, 2995, 2916, 1650, 1606, 1513, 1475, 1446, 1276, 1248, 1171, 1140, 1031, 821, 778 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.20–7.18 (m, 2H, ArH), 6.95–6.93 (m, 2H, ArH), 5.38 (d, *J*=13.6 Hz, 1H, CH=CF), 4.28–4.26 (m, 2H, CH₂N), 3.81 (s, 3H, OCH₃), 3.22–3.17 (m, 2H, CH₂CO). ¹³C NMR (150 MHz, CDCl₃) δ 165.9, 158.1, 150.8 (d, *J*=251 Hz), 133.6, 126.9, 114.2, 97.6 (d, *J*=15.0 Hz), 54.8, 49.8 (d, *J*=38.6 Hz), 29.6(d, *J*=8.6 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ –116.9 to –117.3 (m). HRMS (ESI) *m/z*: calcd for C₁₂H₁₃FNO⁺₂ [M+H]⁺ 222.0925, found 222.0927.

4.2.4.9. 5-Fluoro-1-(4-(trifluoromethyl)phenyl)-1,6-dihydro pyridin-2(3H)-one (**6gb**). Eluent solvent: petroleum ether/ethyl acetate=15/1. White solid, mp 127–128 °C. IR (neat): ν 3441, 2954, 2917, 2849, 1648, 1610, 1442, 1324, 1277, 1165, 1116, 821, 783 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.70 (d, *J*=8.0 Hz, 2H, ArH), 7.45 (d, *J*=8.0 Hz, 2H, ArH), 5.42 (d, *J*=13.6 Hz, 1H, CH=CF), 4.35–4.33 (m, 2H, CH₂N), 3.25–3.21 (m, 2H, CH₂CO). ¹³C NMR (150 MHz, CDCl₃) δ 166.7, 151.2 (d, *J*=251 Hz), 144.6, 129.7 (q, *J*=32.7 Hz), 126.7 (q, *J*=3.5 Hz), 126.6, 123.9 (q, *J*=270 Hz), 98.4 (d, *J*=15.1 Hz), 49.6 (d, *J*=39.6 Hz), 30.5 (d, *J*=8.4 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ –63.13 (s, 3F), -116.5 to -116.6 (m, 1F). HRMS (ESI) *m/z*: calcd for C₁₂H₁₀F₄NO⁺ [M+H]⁺ 261.0711, found 261.0711.

4.2.4.10. 5-Fluoro-1-(3-bromophenyl)-1,6-dihydropyridin-2(3H)one (**6hb**). Eluent solvent: petroleum ether/ethyl acetate=5:2. White solid, mp 126–127 °C. IR (neat): ν 3414, 2955, 2918, 2849, 1663, 1580, 1573, 1476, 1362, 1259, 1178, 1143, 1028, 769 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.47–7.45 (m, 2H, ArH), 7.33–7.24 (m, 2H, ArH), 5.43–5.37 (dt, *J*=13.8, 1.4 Hz, 1H, *CH*=CF), 4.31–4.28 (m, 2H, CH₂N), 3.23–3.19 (m, 2H, CH₂CO). ¹³C NMR (150 MHz, CDCl₃) δ 165.8, 150.6 (d, *J*=251 Hz), 141.9, 130.1, 130.0, 128.9, 124.4, 122.1, 97.6 (d, *J*=14.8 Hz), 49.2 (d, *J*=39.3 Hz), 29.6 (d, *J*=8.6 Hz). ¹⁹F NMR (376 MHz, CDCl₃) δ –116.7 to –116.8 (m). HRMS (ESI) *m/z*: calcd for C₁₁H₁₁BrFNO⁺ [M+H]⁺ 269.9924, found 269.9931.

4.2.4.11. (*E*)-*N*-(2-*Fluoroallyl*)-*N*-(*o*-*tolyl*)*but*-2-*enamide* (**7ib**). Eluent solvent: petroleum ether/ethyl acetate=10:1. White solid, mp 62–63 °C. IR (neat): *v* 3484, 2924, 2852, 1669, 1633, 1492, 1445, 1375, 1206, 1188, 966, 935, 849, 729 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 7.47–7.45 (m, 2H, ArH), 7.33–7.10 (m, 4H, ArH), 7.10–6.90 (m, 1H, MeCH=CH), 5.60–5.50 (dq, *J*=14.8, 1.4 Hz, 1H, MeCH=CH), 4.90–4.70 (dd, *J*=15.2, 15.2 Hz, 1H, CH₂N), 4.66 (dd, *J*=16.0, 3.2 Hz, 1H, CH₂=CF), 4.41 (dd, *J*=48, 3.2 Hz, 1H, CH₂=CF), 3.96 (dd, *J*=48, 3.2 Hz, 1H, CH₂N), 2.19 (s, 3H, ArCH₃), 1.72 (d, *J*=3.4 Hz, 3H, *Me*CH=CH). ¹³C NMR (150 MHz, CDCl₃) δ 165.5, 160.8 (d, *J*=260 Hz), 142.2, 139.4, 135.7, 130.6, 128.6, 127.9, 126.5, 121.1, 93.3 (d, *J*=18 Hz), 47.7 (d, *J*=30 Hz), 17.4, 16.9. ¹⁹F NMR (376 MHz, CDCl₃) δ –101.0 to –102.0 (m). HRMS (ESI) *m/z*: calcd for C₁₄H₁₆FNONa⁺ [M+H]⁺ 256.1108, found 256.1111.

4.2.4.12. (E)-5-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4fluoropent-3-enoic acid (**8ab**). **6ab** (0.235 g, 1.0 mmol) was added to a solution of 6 N HCl aqueous (10 mL), and the mixture was refluxed for 3 h and then concentrated under reduced pressure to dryness, giving a quantitative white solid, mp 52–53 °C. ¹H NMR (400 MHz, D₂O) δ 5.51 (dt, J=20, 8.0 Hz, 1H, CF=CH), 4.41 (d, J=20 Hz, 2H, CH₂CF), 3.04 (d, J=8.0 Hz, 2H, CH₂CO), MS (ESI) *m/z*: 143 [M+H]⁺. The crude mixture was used in the next step without further purification.

Fmoc-Cl (0.310 g, 1.2 mmol) was added at 0 °C to a mixture of the amine hydrochloride (1.0 mmol) in THF and 10% Na₂CO₃ aqueous solution (10/10 mL) and the reaction mixture was stirred at 0 °C for 3 h and was then poured into ice-cooled HCl aqueous solution (1 N, 30 mL) and extracted with AcOEt (3×30 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The crude mixture was purified by column chromatography to afford **8ab** (0.269 g, 76%). Eluent solvent: petroleum ether/ethyl acetate=10:1. White solid, mp 123–124 °C; ¹H NMR (400 MHz, (CD₃)₂CO): δ 3.23 (d, *J*=7.6 Hz, 2H, CH₂CO), 3.90–4.00 (m, 2H, OCH₂CH), 4.00–4.30 (m, 1 H, OCH₂CH), 4.30–4.40 (m, 2 H, CH₂CF), 5.35 (dt, *J*=19.6, 7.6 Hz, 1H, CF=CH), 6.90 (brs, 1 H, NH), 7.25–7.50 (m, 4 H, ArH), 7.60–7.80 (m, 2H, ArH), 7.64–7.66 (m, 2H, ArH); MS (ESI) *m/z*: 356.1 [M+H]⁺. The data is consistent with the reported literature.^{2d}

Acknowledgements

We gratefully acknowledge National Natural Science Foundation of China (No. 21472024 and No. 21242008) for the research financial support.

Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.tet.2016.06.054.

References and notes

- Fluorine in Medicinal Chemistry and Chemical Biology; Ojima, I., Ed.; Wiley: Chichester, 2009.
- (a) Couve-Bonnaire, S.; Cahard, D.; Pannecoucke, X. Org. Biomol. Chem. 2007, 5, 1151; (b) Dutheuil, G.; Couve-Bonnaire, S.; Pannecoucke, X. Angew. Chem., Int. Ed. 2007, 46, 1290; (c) Yamaki, Y.; Shigenaga, A.; Tomita, K.; Narumi, T.; Narumi, T.; Fujii, N.; Otaka, A. J. Org. Chem. 2009, 74, 3272; (d) Pierry, C.; Couve-Bonnaire, S.; Guilhaudis, L.; Neceu, C.; Marotte, A.; Lefranc, B.; Cahard, D.; Segalas-Milazzo, I.; Leprince, J.; Pannecoucke, X. ChemBioChem 2013, 14, 1620; (e) Ameduri, B. Macromolecules 2010, 43, 10163.
- (a) Urban, J. J.; Tillman, B. G.; Cronin, W. A. J. Phys. Chem. A 2006, 110, 11120; (b) Gante, J. Angew. Chem., Int. Ed. 1994, 33, 1699.
- (a) Chang, W.; Mosley, R. T.; Bansal, S.; Keilman, M.; Lam, A. M.; Furman, PhA.; Otto, M. J.; Sofia, M. J. Bioorg. Med. Chem. Lett. 2012, 22, 2938; (b) Edmondson, S. D.; Wei, L.; Xu, J.; Shang, J.; Xu, S.; Pang, J.; Chaudhary, A.; Dean, D. C.; He, H.; Leiting, B.; Lyons, K. A.; Patel, R. A.; Patel, S. B.; Scapin, G.; Wu, J. K.; Beconi, M. G.; Thornberry, N. A.; Weber, A. E. Bioorg. Med. Chem. Lett. 2008, 18, 2409; (c) Kim, H. O.; Yoo, S. J.; Ahn, H. S.; Choi, W. J.; Moon, H. R.; Lee, K. M.; Chun, M. W.; Jeong, L. S. Bioorg. Med. Chem. Lett. 2004, 14, 2091; (d) Wnuk, S. F.; Lalam, J.; Garmendia, C. A.; Robert, J.; Zhu, J.; Pei, D. Bioorg. Med. Chem. 2008, 16, 5090; (e) Burkhart, J. P.; Weintraub, P. M.; Gates, C. A.; Resvick, R. J.; Vaz, R. J.; Friedrich, D.; Angelastro, M. R.; Bey, P.; Peet, N. P. Bioorg. Med. Chem. 2002, 10, 929; (f) Alloatti, D.; Giannini, G.; Cabri, W.; Lustrati, I.; Marzi, M.; Ciacci, A.; Gallo, G.; Tinti, M. O.; Marcellini, M.; Riccioni, T.; Guglielmi, M. B.; Carminati, P.; Pisano, C. J. Med. Chem. 2008, 51, 2708; (g) Gosslau, A.; Pabbaraja, S.; Knapp, S.; Chen, K. Y. Eur. J. Pharmacol. 2008, 587, 25; (h) Oishi, H.; Kaminati, H.; Kodera, Y.; Watanabe, K.; Kobayashi, K.; Narumi, T.; Tomita, K.; Ohno, H.; Naito, T.; Kodama, E.; Matsuoka, M.; Fujii, N. Org. Biomol. Chem. 2009, 7, 2872; (i) Deng, T.; Shan, S.; Li, Z.-B.; Wu, Z.-W.; Liao, C.-Z.; Ko, B.; Lu, X.-P.; Cheng, J.; Ning, Z.-Q. Biol. Pharm. Bull. 2005, 28, 1192.
- (a) Ernet, T.; Maulitz, A. H.; Wurthwein, E.-U.; Haufe, G. J. Chem. Soc., Perkin Trans. 1 2001, 1929; (b) Rosen, T. C.; Yoshida, S.; Kirk, K. L.; Haufe, G. ChemBioChem 2004, 5, 1033; (c) Souzy, R.; Ameduri, B.; Boutevin, B. Prog. Polym. Sci. 2004, 29, 75.
- (a) Landelle, G.; Bergeron, N.; Turcotte-Savard, M.-O.; Paquin, J.-F. Chem. Soc. Rev. 2011, 40, 2867; (b) Yanai, H.; Taguchi, T. Eur. J. Org. Chem. 2011, 5939; (c) Hara, S. Top. Curr. Chem. 2012, 327, 59; (d) Yang, M.-H.; Matikonda, S. S.; Altman, R. A. Org. Lett. 2013, 15, 3894; (e) Song, X.; Chang, J.; Zhu, D.; Li, J.; Xu, C.; Liu, Q.; Wang, M. Org. Lett. 2015, 17, 1712; (f) Zhao, Y.; Jiang, F.; Hu, J. J. Am. Chem. Soc. 2015, 137, 5199.
- 7. Takahira, Y.; Morizawa, Y. J. Am. Chem. Soc. 2015, 137, 7031.
- Salim, S. S.; Bellingham, R. K.; Satcharoen, V.; Brown, R. C. D. Org. Lett. 2003, 5, 3403.
- (a) de Matteis, V.; van Delft, F. L.; Tiebes, J.; Rutjies, F. P. J. T. *Eur. J. Org. Chem.* 2006, 1166; (b) Matteis, V. D.; Dufay, O.; Waalboer, D. C. J.; van Delft, F. L.; Tiebes, J.; Rutjies, F. P. J. T. *Eur. J. Org. Chem.* 2007, 2667; (c) Matteis, V. D.; van Delft, F. L.; Tiebes, J.; Rutjies, F. P. J. T. *Synlett* 2008, 351; (d) Marhold, M.; Stillig, C.; Frohlich, R.; Haufe, G. *Eur. J. Org. Chem.* 2014, 5777; (e) Guerin, D.; Gaumont, A.-C.; Dez, I.; Mauduit, M.; Couve-Bonnaire, S.; Pannecoucke, X. ACS Catal. 2014, 4, 2374; (f) de Matteis, V.; van Delft, F. L.; de Gelder, R.; Tiebes, J.; Rutjies, F. P. J. T. *Tetrahedron Lett.* 2004, 45, 959.
- (a) Niida, A.; Tomita, K.; Mizumoto, M.; Tanigaki, H.; Terada, T.; Oishi, S.; Ohno, H.; Otaka, A.; Inui, K.; Fujii, N. Org. Lett. 2006, 8, 613; (b) Dutheuil, G.; Pierry, C.; Villiers, E.; Couve-bonnaire, S.; Pannecoucke, X. New J. Chem. 2013, 37, 1320.
- (a) Sashuk, V.; Samojlowicz, C.; Szadkowska, A.; Grela, K. *Chem. Comm.* 2008, 2468; (b) Macnaughtan, M. L.; Gary, J. B.; Gerlach, D. L.; Johnson, M. J. A.; Kampf, J. W. *Organometallics* 2009, *28*, 2880.